Key result
Medical therapy for heart failure in ACHD lacks robust evidence, requiring cautious extrapolation from acquired heart disease.
Why the study?
Heart failure drives cardiac mortality in adult congenital heart disease, but clinical trial data, high-quality evidence, and consensus guidelines guiding medical management are lacking.
This review emphasizes the need for population-driven studies in adult congenital heart disease patients with heart failure, as current management relies on cautious extrapolation from acquired heart disease data.
Cardiac mortality in the population of patients with adult congenital heart disease is driven primarily by heart failure. Clinical trial data, high-quality evidence, and consensus guidelines that inform the medical management of the population with acquired heart disease are lacking for those with adult congenital heart disease. These patients require special attention, and although the data can cautiously be extrapolated, in many instances, future population-driven studies are necessary. This review summarizes the most up-to-date data and provides an expert review of heart failure in the patient with adult congenital heart disease focusing on epidemiology, staging, and available pharmacological therapies.
No takes yet. Share an insight, caveat, or question.
Ortega–Legaspi et al. (2025) conducted a review in Heart failure in adult congenital heart disease. Pharmacological therapies was evaluated. Medical management of heart failure in adult congenital heart disease lacks high-quality evidence, requiring cautious extrapolation of data from acquired heart disease populations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: